Goldman Sachs raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $37 from $30 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
- Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
- NewAmsterdam Pharma Reports Q3 2025 Financial Results
- Positive Outlook for NewAmsterdam Pharma: Strong Q3 Performance and Promising Developments
- NewAmsterdam Pharma’s Promising Developments and EU Approval Prospects Drive Buy Rating